CN103588778A - Strontium cantharidate and preparation method thereof - Google Patents
Strontium cantharidate and preparation method thereof Download PDFInfo
- Publication number
- CN103588778A CN103588778A CN201310571217.3A CN201310571217A CN103588778A CN 103588778 A CN103588778 A CN 103588778A CN 201310571217 A CN201310571217 A CN 201310571217A CN 103588778 A CN103588778 A CN 103588778A
- Authority
- CN
- China
- Prior art keywords
- strontium
- cantharidate
- cantharidin
- trichloromethane
- isopropanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses strontium cantharidate. A structural formula (I) of the strontium cantharidate is as follows. A preparation method of the strontium cantharidate comprises the steps as follows: according to the weight ratio of 1:(30-50), trichloromethane or isopropanol is added into a cantharidin pure product and heated, so that the mixture is dissolved; at the same time, strontium hydroxide is added into isometric distilled water of the trichloromethane or the isopropanol, uniform mixing is performed, and the molar ratio of cantharidin to the strontium hydroxide is in a range of (3:1)-(3:2); a strontium hydroxide solution is added into a trichloromethane solution or an isopropanol solution which dissolves the cantharidin, and magnetic stirring is performed for 6-12 hours; after stirring, the mixture is heated to 60-75 DEG C, and the trichloromethane or the isopropanol is volatilized, so that a white suspension is obtained; the suspension is placed into a drying oven, concentrated and dried, so that white crystal powder is obtained; and according to the weight ratio of (30-50):1, the trichloromethane or the isopropanol is added into the white crystal powder and heated to 40 DEGC, the temperature is kept until the cantharidin is dissolved, then filtering and drying are performed, and white crystal powder is obtained, so that the strontium cantharidate is obtained. The strontium cantharidate and the preparation method thereof have the characteristics as follows: the antitumor activity is higher, the process is simple, the operation is facilitated, the safety is good, the finished product performance is stable, and the purity is high.
Description
Technical field
The invention belongs to technical field of chemistry, particularly cantharidate strontium also relates to the preparation method that this removes cantharidate strontium simultaneously.
Background technology
Cantharidin is the defensive material of Chinese blister beetle secretion, has good anticancer effect, and the kinds cancers such as primary hepatocarcinoma, ascitic type liver cancer are had to good therapeutic action.The current Cantharidin medicine with exploitation has multiple, has all obtained good clinical application.Because Cantharidin is water insoluble, be often used as oral pharmaceutical application, but Cantharidin has severe toxicity, has medicine if oral, can cause a series of digestive tract diseases such as damage of intestinal mucosa, and absorbed power is not high, reduced its anticancer effect, also limited the range of application of Cantharidin.
The chemical constitution study of Chinese blister beetle polypide shows to contain in Chinese blister beetle Cantharidin, formic acid, pigment, grease, various trace elements; These trace elements comprise the different Fe of content, Al, Zn, Ni, Pb etc.Cantharidin in Chinese blister beetle polypide is cantharidinic anhydride, and contriver wishes by the research to the metal-salt of Cantharidin, to finding toxicity less, and the better Cantharidin hydrochlorate of anti-tumor activity.
Successfully developed at present cantharidate sodium, water-soluble by increasing, its toxicity also decreases, utilize this excellent properties, developed cantharidate sodium injection, can apply by direct injection, current cantharidate sodium injection has been successfully applied to clinical, and has obtained significant effect.But cantharidate sodium is falling the hypotoxic while, antitumour activity, along with great reduction, therefore solves this problem in the urgent need to developing other new more cantharidin derivatives of high anti-cancer activity that have.
Compound and the correlative study achievement thereof of cantharidate strontium are not still disclosed up to now.
Summary of the invention
The object of the invention is to overcome above-mentioned shortcoming and a kind ofly having compared with high anti-cancer activity of providing, technique is simple, easy handling, and security is good, and end properties is stable, the cantharidate strontium that purity is high.
Another object of the present invention is to provide the preparation method of this cantharidate strontium.
Cantharidate strontium of the present invention, its structural formula (I) is:
The preparation method of a kind of cantharidate strontium of the present invention, comprises the steps:
(1) by the weight ratio of 1:30-50, in Cantharidin sterling, add trichloromethane or Virahol, heating makes its dissolving; Get Cantharidin simultaneously: the strontium hydroxide that strontium hydroxide mol ratio is 3:1-3:2, join with trichloromethane or the isopyknic distilled water of Virahol in, mix; Strontium hydroxide solution is joined in the chloroform soln or aqueous isopropanol that dissolves Cantharidin to magnetic agitation 6-12 hour.
(2) stir post-heating after 60-75 ℃, trichloromethane or Virahol are volatilized, obtain white suspension; Put in baking oven and concentrate, dry, obtain white crystalline powder;
(3) by the weight ratio of 30-50:1, trichloromethane or Virahol are joined in white crystalline powder, be heated to 40 ℃ and keep this temperature that Cantharidin is dissolved, filter, dry, obtain white crystalline powder, obtain.
A further object of the present invention is to provide the pharmaceutical composition that comprises cantharidate strontium and pharmaceutically acceptable carrier.
Described pharmaceutically acceptable carrier can need to carry out routine according to preparation process to be chosen, and comprises the weighting agent used of preparation solid dosage, tackiness agent, lubricant, disintegrating agent, antioxidant etc., and the solvent, antioxidant etc. of preparing liquid dosage form.For example, weighting agent can be selected from lactose, sucrose, starch, methylcellulose gum, Microcrystalline Cellulose, dextrin etc.; Tackiness agent can be selected from water, alcohol, gelatin etc.; Lubricant can be selected from talcum, Magnesium Stearate etc.; Disintegrating agent can be selected from calcium carbonate, sodium bicarbonate, sodium alginate etc.; Antioxidant can be selected from titanium dioxide etc., and solvent can be selected from water, ethanol, propyl alcohol, glycerine etc.According to preparation, need, can also choose other carrier or auxiliary material.
Beneficial effect of the present invention, from above technical scheme, it is simple that the present invention has technique, easy handling, the cantharidate strontium obtaining is an analog derivative of Cantharidin, has the antitumor mechanism similar to Cantharidin, experimental results show that it has higher antitumour activity.And molecular weight is little, easily enter in cancer cells, produce cytotoxicity, thereby there is stronger antitumor action, be a kind of comparatively desirable cancer therapy drug.Can be mainly used in the treatment of late primary liver cancer and advanced lung cancer clinically.Its security is good.The finished product stable in properties that present method makes, purity is high.Because it has water-solublely preferably, the antitumor drug that can be applicable to the multiple formulations such as injection, solution, ointment is produced.
Embodiment
Below in conjunction with specific embodiment, the present invention is further described, but does not limit the invention to these embodiments.One skilled in the art would recognize that the present invention contained all alternativess, improvement project and the equivalents that within the scope of claims, may comprise.
Embodiment 1:
A preparation method for cantharidate strontium, comprises the steps:
(1) in 100mL Erlenmeyer flask, add 0.588g Cantharidin, add 25mL trichloromethane, heating makes its dissolving; Take strontium hydroxide 0.122g simultaneously, add in 25mL distilled water, mix.Strontium hydroxide solution is joined in the chloroform soln or aqueous isopropanol that dissolves Cantharidin to magnetic agitation 6 hours.
(2) stir after post-heating to 60 ℃, trichloromethane is volatilized, obtain white suspension; Put in baking oven and concentrate, dry, obtain white crystalline powder;
(3) trichloromethane of 30ml is joined in white crystalline powder, be heated to 40 ℃ of constant temperature 2 hours, Cantharidin is dissolved, filter, dry, obtain white crystalline powder and be cantharidate strontium sterling.
Embodiment 2:
A preparation method for cantharidate strontium, comprises the steps:
(1) in the Erlenmeyer flask of 1000ml, add Cantharidin sterling 5.88g, add 290ml aqueous isopropanol, heating makes its dissolving; Take strontium hydroxide 1.22g simultaneously, add in 290mL distilled water, mix.Strontium hydroxide solution is joined in the aqueous isopropanol that dissolves Cantharidin to magnetic agitation 6 hours.
(2) stir after post-heating to 75 ℃, Virahol is volatilized, obtain white suspension; Put in baking oven and concentrate, dry, obtain white crystalline powder;
(3) trichloromethane of 290ml is joined in white crystalline powder, be heated to 40 ℃ of constant temperature 2 hours, Cantharidin is dissolved, filter, dry, obtain white crystalline powder and be cantharidate strontium sterling.
Embodiment 3: product purity inspection
Cantharidate strontium does not have the quality determination standard of national regulation, therefore the measuring method with reference to the cantharidate sodium national drug standards [standard No.: WS-10001-(HD-0044)-2002] is measured at this.
Assay
Chromatographic condition and system suitability be take octadecylsilane chemically bonded silica as weighting agent; Methanol-water (51:49) is moving phase; Flow velocity is 1.0ml/min; Detection wavelength is 227nm; Sensitivity is 0.005AUFS.Number of theoretical plate is pressed Cantharidin peak and is calculated, and should be not less than 2000.
The preparation of reference substance solution: get Cantharidin reference substance appropriate, accurately weighed, add methyl alcohol and make every 1ml containing the solution of Cantharidin 0.15mg, in contrast product solution.
The preparation of need testing solution: precision takes this product 10mg, to 100ml flask, adds 50ml water, then adds 1mol/L H
2sO
4solution 10ml, shake up, put in 65 ℃ of water-baths and reflux 30 minutes, move in separating funnel after slightly cold, with trichloromethane 25ml, 15ml, 10ml extraction three times, each 10 minutes, combining extraction liquid, put in 70 ℃ of water-baths and volatilizes solvent, residue turns and holds to 50ml measuring bottle with methyl alcohol, constant volume, shakes up, and is need testing solution.
Assay method: precision is drawn reference substance solution and each 20 μ l of need testing solution respectively, injection liquid chromatography, records color atlas, with external standard method, calculates Cantharidin content, be multiplied by again the molecular weight of the molecular weight/Cantharidin of 1.53(cantharidate strontium), obtain cantharidate content of strontium.
The cantharidate strontium purity that detected result embodiment 1,2 obtains is more than 90%.
Claims (3)
1. cantharidate strontium, its structural formula (I) is:
2. the preparation method of cantharidate strontium as claimed in claim 1, comprises the steps:
(1) by the weight ratio of 1:30-50, in Cantharidin sterling, add trichloromethane or Virahol, heating makes its dissolving; Get Cantharidin simultaneously: the strontium hydroxide that strontium hydroxide mol ratio is 3:1-3:2, join with trichloromethane or the isopyknic distilled water of Virahol in, mix; Strontium hydroxide solution is joined in the chloroform soln or aqueous isopropanol that dissolves Cantharidin to magnetic agitation 6-12 hour.
(2) stir post-heating after 60-75 ℃, trichloromethane or Virahol are volatilized, obtain white suspension; Put in baking oven and concentrate, dry, obtain white crystalline powder; (3) by the weight ratio of 30-50:1, trichloromethane or Virahol are joined in white crystalline powder, be heated to 40 ℃ and keep this temperature that Cantharidin is dissolved, filter, dry, obtain white crystalline powder, obtain.
3. pharmaceutical composition, comprises cantharidate strontium as claimed in claim 1 and pharmaceutically acceptable additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310571217.3A CN103588778A (en) | 2013-11-15 | 2013-11-15 | Strontium cantharidate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310571217.3A CN103588778A (en) | 2013-11-15 | 2013-11-15 | Strontium cantharidate and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103588778A true CN103588778A (en) | 2014-02-19 |
Family
ID=50079130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310571217.3A Pending CN103588778A (en) | 2013-11-15 | 2013-11-15 | Strontium cantharidate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103588778A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923098A (en) * | 2014-04-23 | 2014-07-16 | 遵义医学院 | Preparation of demethylated strontium cantharidate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076111A (en) * | 1992-03-11 | 1993-09-15 | 王日卫 | Cantharidate anti-virus formulation and preparation thereof |
| CN1091953A (en) * | 1993-03-10 | 1994-09-14 | 王曰卫 | Cantharidate anti-virus formulation and preparation thereof |
| CN102093383A (en) * | 2011-01-30 | 2011-06-15 | 遵义医学院 | Potassium cantharidate and preparation method thereof |
| CN102250110A (en) * | 2011-06-03 | 2011-11-23 | 遵义医学院 | Magnesium cantharidate and preparation method thereof |
| CN102295648A (en) * | 2011-06-03 | 2011-12-28 | 遵义医学院 | Calcium cantharidinate and preparation method thereof |
-
2013
- 2013-11-15 CN CN201310571217.3A patent/CN103588778A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076111A (en) * | 1992-03-11 | 1993-09-15 | 王日卫 | Cantharidate anti-virus formulation and preparation thereof |
| CN1091953A (en) * | 1993-03-10 | 1994-09-14 | 王曰卫 | Cantharidate anti-virus formulation and preparation thereof |
| CN102093383A (en) * | 2011-01-30 | 2011-06-15 | 遵义医学院 | Potassium cantharidate and preparation method thereof |
| CN102250110A (en) * | 2011-06-03 | 2011-11-23 | 遵义医学院 | Magnesium cantharidate and preparation method thereof |
| CN102295648A (en) * | 2011-06-03 | 2011-12-28 | 遵义医学院 | Calcium cantharidinate and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李晓飞，等.: "芫菁体内斑蝥素的含量及存在形式", 《昆虫学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923098A (en) * | 2014-04-23 | 2014-07-16 | 遵义医学院 | Preparation of demethylated strontium cantharidate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107827724B (en) | Curcumin-2, 5-dihydroxybenzoic acid eutectic crystal and preparation method thereof | |
| CN104689337B (en) | A kind of method that utilization metal-organic framework materials load 5 fluorouracils | |
| JP2019509332A (en) | Baicalin magnesium compound, its production method and use | |
| CN101095670B (en) | Luteolin phospholipid complexes and method for preparing the same and application thereof | |
| CN110128356A (en) | A kind of Gefitinib and 3- hydroxybenzoic acid eutectic | |
| CN101434635B (en) | Water-soluble phenolic triterpenoid with antineoplastic activity and preparation thereof | |
| CN110156700A (en) | Gefitinib and salicylic acid eutectic | |
| CN103588780A (en) | Barium cantharidate and preparation method thereof | |
| CN112441952B (en) | Cannabidiol-3-sulfonic acid, preparation method and application thereof, and cannabidiol derivative | |
| CN102093383A (en) | Potassium cantharidate and preparation method thereof | |
| CN102250110B (en) | Magnesium cantharidate and preparation method thereof | |
| CN109400598B (en) | Eutectic crystal of berberine hydrochloride and lactic acid, preparation method and application thereof | |
| CN102295648B (en) | Calcium cantharidinate and preparation method thereof | |
| CN108084177B (en) | A kind of jamaicin 9- pyrazole derivatives and its preparation and application | |
| US11021476B2 (en) | Pyrroloquinoline quinone monosodium and method for producing the same, and composition comprising the same | |
| CN104788421A (en) | Erdosteine compound for treating respiratory tract inflammation and preparation method of erdosteine compound | |
| CN103588778A (en) | Strontium cantharidate and preparation method thereof | |
| CN103588779A (en) | Manganese cantharidate and preparation method thereof | |
| CN108484624B (en) | Irinotecan hydrochloride impurity and synthesis method and application thereof | |
| WO2018014368A1 (en) | Water-soluble isatin derivative, and manufacturing method and application thereof | |
| CN103319390A (en) | Alprostadil compound and composition thereof | |
| CN103845332A (en) | Medicinal dasatinib composition and preparation method thereof | |
| CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
| CN106074420B (en) | A kind of preparation method of the silybin meglumine tablets of high bioavilability | |
| CN102973527A (en) | Method for self-assembling and preparing thermo-sensitive nano drug-loaded microspheres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140219 |